Even more important, p38 inhibitors - which are in clinical trial for diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease, and multiple myeloma - are likely less toxic than PI3K, AKT, and mTOR inhibitors and could therefore be preferred for combination therapies. Here, MTOR is linked to chronic obstructive pulmonary disease.